Islets from human donors with higher but not lower hemoglobin A1c levels respond to gastrin treatment in vitro.
Gastrin is a peptide hormone, which in combination with other factors such as TGFα, EGF or GLP-1, is capable of increasing beta cell mass and lowering blood glucose levels in adult diabetic mice. In humans, administration of a bolus of gastrin alone induces insulin secretion suggesting that gastrin...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0221456 |
id |
doaj-10def19254c942c0a16090f99949c62a |
---|---|
record_format |
Article |
spelling |
doaj-10def19254c942c0a16090f99949c62a2021-03-03T22:18:20ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01148e022145610.1371/journal.pone.0221456Islets from human donors with higher but not lower hemoglobin A1c levels respond to gastrin treatment in vitro.Ayelet LenzGal LenzHsun Teresa KuKevin FerreriFouad KandeelGastrin is a peptide hormone, which in combination with other factors such as TGFα, EGF or GLP-1, is capable of increasing beta cell mass and lowering blood glucose levels in adult diabetic mice. In humans, administration of a bolus of gastrin alone induces insulin secretion suggesting that gastrin may target islet cells. However, whether gastrin alone is sufficient to exert an effect on isolated human islets has been controversial and the mechanism remained poorly understood. Therefore, in this study we started to examine the effects of gastrin alone on cultured adult human islets. Treatment of isolated human islets with gastrin I for 48 h resulted in increased expression of insulin, glucagon and somatostatin transcripts. These increases were significantly correlated with the levels of donor hemoglobin A1c (HbA1c) but not BMI or age. In addition, gastrin treatment resulted in increased expression of PDX1, NKX6.1, NKX2.2, MNX1 and HHEX in islets from donors with HbA1c greater than 42 mmol/mol. The addition of YM022, an antagonist of the gastrin receptor cholecystokinin B receptor (CCKBR), together with gastrin eliminated these effects, verifying that the effects of gastrin are mediated through CCKBR.CCKBR is expressed in somatostatin-expressing delta cells in islets from all donors. However, in the islets from donors with higher HbA1c (greater than 42 mmol/mol [6.0%]), cells triple-positive for CCKBR, somatostatin and insulin were detected, suggesting a de-differentiation or trans-differentiation of endocrine cells. Our results demonstrate a direct effect of gastrin on human islets from prediabetic or diabetic individuals that is mediated through CCKBR+ cells. Further, our data imply that gastrin may be a potential treatment for diabetic patients.https://doi.org/10.1371/journal.pone.0221456 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ayelet Lenz Gal Lenz Hsun Teresa Ku Kevin Ferreri Fouad Kandeel |
spellingShingle |
Ayelet Lenz Gal Lenz Hsun Teresa Ku Kevin Ferreri Fouad Kandeel Islets from human donors with higher but not lower hemoglobin A1c levels respond to gastrin treatment in vitro. PLoS ONE |
author_facet |
Ayelet Lenz Gal Lenz Hsun Teresa Ku Kevin Ferreri Fouad Kandeel |
author_sort |
Ayelet Lenz |
title |
Islets from human donors with higher but not lower hemoglobin A1c levels respond to gastrin treatment in vitro. |
title_short |
Islets from human donors with higher but not lower hemoglobin A1c levels respond to gastrin treatment in vitro. |
title_full |
Islets from human donors with higher but not lower hemoglobin A1c levels respond to gastrin treatment in vitro. |
title_fullStr |
Islets from human donors with higher but not lower hemoglobin A1c levels respond to gastrin treatment in vitro. |
title_full_unstemmed |
Islets from human donors with higher but not lower hemoglobin A1c levels respond to gastrin treatment in vitro. |
title_sort |
islets from human donors with higher but not lower hemoglobin a1c levels respond to gastrin treatment in vitro. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2019-01-01 |
description |
Gastrin is a peptide hormone, which in combination with other factors such as TGFα, EGF or GLP-1, is capable of increasing beta cell mass and lowering blood glucose levels in adult diabetic mice. In humans, administration of a bolus of gastrin alone induces insulin secretion suggesting that gastrin may target islet cells. However, whether gastrin alone is sufficient to exert an effect on isolated human islets has been controversial and the mechanism remained poorly understood. Therefore, in this study we started to examine the effects of gastrin alone on cultured adult human islets. Treatment of isolated human islets with gastrin I for 48 h resulted in increased expression of insulin, glucagon and somatostatin transcripts. These increases were significantly correlated with the levels of donor hemoglobin A1c (HbA1c) but not BMI or age. In addition, gastrin treatment resulted in increased expression of PDX1, NKX6.1, NKX2.2, MNX1 and HHEX in islets from donors with HbA1c greater than 42 mmol/mol. The addition of YM022, an antagonist of the gastrin receptor cholecystokinin B receptor (CCKBR), together with gastrin eliminated these effects, verifying that the effects of gastrin are mediated through CCKBR.CCKBR is expressed in somatostatin-expressing delta cells in islets from all donors. However, in the islets from donors with higher HbA1c (greater than 42 mmol/mol [6.0%]), cells triple-positive for CCKBR, somatostatin and insulin were detected, suggesting a de-differentiation or trans-differentiation of endocrine cells. Our results demonstrate a direct effect of gastrin on human islets from prediabetic or diabetic individuals that is mediated through CCKBR+ cells. Further, our data imply that gastrin may be a potential treatment for diabetic patients. |
url |
https://doi.org/10.1371/journal.pone.0221456 |
work_keys_str_mv |
AT ayeletlenz isletsfromhumandonorswithhigherbutnotlowerhemoglobina1clevelsrespondtogastrintreatmentinvitro AT gallenz isletsfromhumandonorswithhigherbutnotlowerhemoglobina1clevelsrespondtogastrintreatmentinvitro AT hsunteresaku isletsfromhumandonorswithhigherbutnotlowerhemoglobina1clevelsrespondtogastrintreatmentinvitro AT kevinferreri isletsfromhumandonorswithhigherbutnotlowerhemoglobina1clevelsrespondtogastrintreatmentinvitro AT fouadkandeel isletsfromhumandonorswithhigherbutnotlowerhemoglobina1clevelsrespondtogastrintreatmentinvitro |
_version_ |
1714812696093786112 |